Business
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a
About this update from Mediwound Ltd.
[{"type":"text","content":"MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Vericel reported that the contract is for the procurement of NexoBrid, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S.-based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid. Vericel further reported that the base period contract of $35 million includes approximately $10 million over the next 12 months for the initial procurement of NexoBrid for the U.S. Strategic National Stockpile and VMI establishment, funding for VMI-related services and initial development activities for a potential expanded NexoBrid indication for the treatment of blast trauma injuries. According to Vericel, the ten-year contract, effective as of April 1, 2026, also includes optional awards for additional NexoBrid procurement to expand the Strategic National Stockpile, further clinical development for a potential blast trauma indication, design and validation of a potential U.S.-based manufacturing facility and the development and procurement of a room temperature stable formulation of NexoBrid. About NexoBrid® NexoBrid is a topically administered, biological orphan drug for the enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. It selectively removes non-viable tissue while preserving viable tissue and is approved for use in adults and pediatric patients in over 40 countries, including the United States, European Union, and Japan. NexoBrid development has been supported with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), under contract HHSO100201500035C.About MediWound Ltd. About MediWound MediWound Ltd. (Nasdaq: MDWD) i...